使用非类固醇抗炎药物在患有高级活性风湿性关节炎的患者中
Dubravka Bobek1,2,3, Andrea Banić Stipetić4, Miljenko Franić2,3,5,6
1Dubrava University Hospital, Department of Physical and Rehabilitation Medicine with Rheumatology, Zagreb, Croatia.
Acta clinica Croatica
|October 23, 2023
概括
许多类风湿性关节炎 (RA) 患者使用非类固醇抗炎药物 (NSAID). 它们的使用与功能状态有关,而不是疾病活性,并且可以减少葡萄糖皮质激素的依赖.
科学领域:
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 类风湿性关节炎 (RA) 管理通常涉及非类固醇抗炎药物 (NSAIDs).
- 了解NSAID使用模式和RA患者的影响因素对于优化治疗和最大限度地减少副作用至关重要.
研究的目的:
- 调查NSAID在活跃类风湿性关节炎 (RA) 患者中使用的规律性.
- 为了确定NSAID使用是否与疾病活性,疼痛强度或功能状态相关.
- 为了确定与NSAID使用相关的胃肠道 (GI) 副作用的风险因素.
主要方法:
- 一项为期6个月的横截面单中心研究,涉及连续住院的RA患者.
- 使用经过验证的工具评估日常生活活动,疼痛强度和疾病活动 (健康评估问卷,视觉模拟尺度,28关节疾病活动得分).
主要成果:
- 在73名RA患者中,66%定期使用NSAIDs.
- 与非使用者相比,NSAID使用者使用葡萄糖皮质类药物的可能性较低.
- 使用NSAID的决定独立于疾病活性,疼痛,功能状态或胃肠道风险因素.
- 较高的功能障碍与较长的NSAID和葡萄糖皮质激素使用时间相关.
结论:
- 无 NSAID 仍然是类风湿性关节炎的相关治疗选择.
- 在RA中NSAID的启动不仅取决于疾病活性或疼痛水平.
- 长期使用NSAID与RA患者的功能障碍较高有关.
- 使用NSAID可以减少对葡萄糖皮质激素的依赖,减轻类固醇相关的不良影响.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
170
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
170
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
122
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
122
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
148
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
148
01:21Rheumatic Heart Disease III: Medical Management
11
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
11
01:29Drugs for Treatment of Ulcerative Colitis in IBD
149
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
149
01:29Inflammatory Bowel Disease IV: Pharmacological Management
134
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
134